As an FDA-approved drug with relatively low toxicity, clonidine can simultaneously target multiple Wnt pathway targets, namely FZD1, Dvl2, and LRP6, and it has demonstrated greater inhibition of colorectal and breast cancers; studies with clonidine have also provided insights for research on the application of Wnt inhibitors in the treatment of gastric cancer (9). Here, DVL2 is linked to gastric cancer.